TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma

Cancer Letters

Volumn 275, Issue 2, 2009, Pages 234-239

  Hosny, Gihan ^a   Farahat, Nahla ^b   Hainaut, Pierre ^c  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

CFDNA; Egypt; Non Hodgkin's lymphoma; P53 mutations; TP53

Indexed keywords

ARGININE; DNA; PHENYLALANINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; EGYPT; EXON; FEMALE; GENE MUTATION; HEPATITIS C VIRUS; HUMAN; MALE; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCREENING TEST;

ADULT; AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA; DNA PRIMERS; EGYPT; EXONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

HEPATITIS C VIRUS; MAMMALIA;

EID: 59549099926     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.029     Document Type: Article

References (34)

1. In: Stewart B.W., and Kleihues P. (Eds). World Cancer Report (2003), International Agency for Research on Cancer, Lyon, France
2. D.M. Parkin, M. Ferlay, M. Hamdi-Cherif, F. Sitas, J. Thomas, H. Wabinga, et al., Cancer in Africa: Epidemiology and Prevention, IARC Scientific Publication No. 153, International Agency for Research on Cancer, Lyon, France, 2003.
3. International Agency for Research on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to Human, vol. 67, Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses, International Agency for Research on Cancer, Lyon, France, 1996.
4. Baecklund E., Sundstrom C., Ekbom A., Catrina A.I., Biberfeld P., Feltelius N., et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 48 (2003) 1543-1550
5. Mueller N.E., Mohar A., and Evans A. Viruses other than HIV and non-Hodgkin's lymphoma. Cancer Res. 52 (1992) 5479s-5481s
6. Nagore E., Ledesma E., Collado C., Oliver V., Perez-Perez A., and Aliaga A. Detection of Epstein-Barr virus and human herpes virus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br. J. Dermatol. 143 (2000) 320-323
7. Killebrew D., and Shiramizu B. Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr. HIV Res. 2 (2004) 215-221
8. Cowgill K.D., Loffredo C.A., Eissa S.A.-L., Mokhtar N., Abdel-Hamid M., Fahmy A., and Strickland C.T. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int. J. Epidemiol. 33 (2004) 1-6
9. Eissa S., Mokhtar N., Abdel-Hamid M., and Fahmy A. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int. J. Epidemiol. 33 5 (2004) 1034-1039
10. Bahnassi A.A., El-Houssini S., Mokhtar N.M., Khaled H.M., El-Mishad A.M., and Zekri A.R. Correlation between HCV-NS3p and p53, p21waf, MDM2, p21, Ras, and C-erb2 in HCV associated hepatocellular carcinoma and adjacent pericarcinomatous foci. J. Egypt. Nat Cancer Inst. 14 1 (2002) 75-85
11. Anker P., Mulcahy H., Chen X.Q., and Stroun M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18 (1999) 65-73
12. Anker P., Mulcahy H., and Stroun M. Circulating DNA in plasma or serum. Int. J. Cancer 103 (2003) 149-152
13. Gormally E., Caboux E., Vineis P., and Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 635 (2007) 105-117
14. Hosny G., Farahat N., Tayel H., and Hainaut P. Ser-249 TP53 and CTNNB1 Mutations in Circulating Free DNA of Egyptian patients with heptocellular carcinoma versus chronic liver diseases. Cancer Lett. 264 (2008) 201-208
15. Hollstein M.C., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
16. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
17. Levine A.J. p53: the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
18. Ichikawa A., Hotta T., Takagi N., Tsushita K., Kinoshita T., Nagai H., Murakami Y., Hayashi K., and Saito H. Mutations of p53 gene and their relation to diseases progression in B-cell lymphoma. Blood 79 (1992) 2701-2709
19. Nagai H., Kinoshita T., Imamura J., Murakami Y., Hayashi K., Mukai K., Ikeda S., Tobinai K., Saito H., Shimoyama M., and Shimotohono K. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn. J. Cancer Res. 82 (1991) 1421-1427
20. Leroy K., Haioun C., Lepage E., Le Metayer N., Berger F., Labouyrie E., Meignin V., Petit B., Bastard C., Salles G., Gisselbrecht C., Reyes F., and Gaulard Ph. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann. Oncol. 13 (2002) 1108-1115
21. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K., Saito H., and Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Eng. J. Med. 337 (1997) 529-534
22. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Knowles D.M., Dalla-Favera R., Neri A., Newcomb E.W., and Magrath I.T. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88 12 (1991) 5413-5417
23. Quintanilla-Matinez L., Kremer M., Keller G., Nathrath M., Gamboa-Dominguez A., Meneses A., Luna-Contreras L., Cabras A., Hoefler H., Moher A., and Fend F. p53 mutations in nasal natural killer/T-cell lymphoma from Mexico. Am. J. Pathol. 159 6 (2001) 2095-2105
24. Koduru P.R.K., Raju K., Vadmal V., Menezes G., Shah S., Susin M., Kolitz J., and Broome J.D. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90 10 (1997) 4078-4091
25. Nagai H., Kinoshita T., Ichikawa A., and Murate T. Malignant lymphoma and tumor suppressor genes. J. Clin. Exp. Hematopathol. 42 1 (2002) 11-24
26. Peller S., and Rotter V. TP53 in hematological cancer, low incidence of mutations with significant clinical relevance. Hum. Mutat. 21 (2003) 277-284
27. Kirk G.D., Lesi O.A., Mendy M., Szymanska K., Whittle H., Goedert J.J., Hainaut P., and Montesano R. 249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24 (2005) 5858-5867
28. Szymanska K., Lesi O.A., Kirk G.D., Sam O., Taniere P., Scoazec J.-Y., Mendy M., Friesen M.D., Whittle H., Montesano R., and Hainaut P. Ser-249 TP53 mutation in tumour and plasma DNA of Hepatocellular carcinoma from a high incidence area in the Gambia, West Africa. Int. J. Cancer 110 (2004) 374-379
29. Sander C.A., Yano T., Clark H.M., Harris C., Lonogo D.L., Jaffe E.S., and Raffeld M. p53 mutation is associated with poor progression in follicular lymphoma. Blood 82 (1993) 1994-2004
30. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., and Shirakusa T. Mutations of p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst. 85 (1993) 2018-2023
31. Oda T., Tsuda H., Scarpa A., Sakamoto M., and Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 15 22 (1992) 6358-6364
32. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 6 (2007) 622-629
33. Gormally E., Vineis P., Matullo G., et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66 13 (2006) 6871-6876
34. Gormally E., Hainaut P., Caboux E., et al. Amount of DNA in plasma and cancer risk: a prospective study. Int. J. Cancer 111 (2004) 746-749